Danaher: Tariffs Impact & China Supply Chain
Former Supply Chain Executive at Pall
inpractise.com/articles/danaher-tariffs-impact-and-china-supply-chain
Danaher: Tariffs Impact & China Supply Chain(June 9, 2025)
Former Supply Chain Executive at Pall
Interview Transcript
This is a snippet of the transcript, sign up to read more.
What were the results there? In addition to the 20% of direct material inputs, which I understand for the whole supply chain are from China, how much more was there?
Often, it was significant. As much as 50% came from China, even though we were buying from a US company. Over 50% of the content could be considered sourced specifically from China.
This is a snippet of the transcript, sign up to read more.
Could you elaborate on the price differential? Specifically, how did it compare with Chinese options in some cases?
The price differential was significant, ranging from 40% to 60% in some areas. When the price differential was smaller, the total equation might suggest maintaining a more robust supply chain rather than pursuing 10% or 15% savings.
This is a snippet of the transcript, sign up to read more.
Could you elaborate on the price differential? Specifically, how did it compare with Chinese options in some cases?
Generally, when sourcing from China or other lower-cost regions, the guideline was that if you didn't see 30% savings, it might be better to source elsewhere. However, anything offering savings greater than 30% was a prime candidate for sourcing from a lower-cost region, particularly China.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher Supply Chain Structure & Potential Tariff-Related Risks
Former Supply Chain Leader at Danaher Corporation
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Danaher: M&A Runway, Target Evaluation Process & Valuations
Former VP Life Science Group at Danaher
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.